OncologyTube Professional - Patients Click Here
218,773 video views
obr: Videos
Benjamin Philip Levy, MD, talks about the data from Keynote 189, specifically, how chemotherapy should be combined with immunotherapy in the treatment of 1st line non-small cell lung cancer (NSCLC)
by:obr | 84 views
Primo N. Lara, Jr., MD, explains whether the TKIs used in the treatment of renal cell carcinoma (RCC) are interchangeable and which TKIs seem to be the most successful in 1st line renal cell carcinoma (RCC)
by:obr | 78 views
Howard A. "Skip" Burris III, MD, FACP, FASCO, explains some of the new and exciting concepts in clinical trial design
by:obr | 56 views
Douglas W. Blayney, MD, explains the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer
by:obr | 68 views
Neelima Denduluri, MD, shares the results of the PERSEPHONE trial in early HER2+ breast cancer mean that 6 months of trastuzumab can be given rather than 12 months in the adjuvant setting
by:obr | 85 views
Julie Gralow, MD, talks about how to differentiate CDK4/6 inhibitors and whether they can be used interchangeably.
by:obr | 45 views
Primo N. Lara, Jr., MD, explains the convenience factor of oral TKIs influences decisions related to advanced renal cell carcinoma (RCC) treatment
by:obr | 36 views
Eunice Wang, MD, talks about The most exciting data coming out of the 2018 Annual Meeting
by:obr | 21 views
Lisa Rometty, Vice President and General Manager, Oncology, Life Sciences, and Personal Health, IBM Watson Health, shares how Watson is helping to identify and match cancer patients to clinical trials at the point of care
by:obr | 29 views
Benjamin Philip Levy, MD, explains whether every non-small cell lung cancer (NSCLC) patient should be tested for PD-L1 expression and what levels of PD-L1 expression are actionable
by:obr | 36 views